ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir

Publikation

ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir

Wissenschaftlicher Artikel/Review - 01.04.2010

Lubomirov Rubin, Telenti Amalio, Csajka Chantal, Decosterd Laurent A, Buclin Thierry, Descombes Patrick, Rentsch Katharina, Ledergerber Bruno, Cavassini Matthias, Calmy Alexandra, Vernazza Pietro, Furrer Hansjakob, Marzolini Catia, Martinez Raquel, Colombo Sara, Fayet Aurélie, di Iulio Julia, Swiss HIV Cohort Study

Zitation

Lubomirov R, Telenti A, Csajka C, Decosterd L, Buclin T, Descombes P, Rentsch K, Ledergerber B, Cavassini M, Calmy A, Vernazza P, Furrer H, Marzolini C, Martinez R, Colombo S, Fayet A, di Iulio J, Swiss HIV Cohort Study. ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. Pharmacogenet Genomics 2010; 20:217-30.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Pharmacogenet Genomics 2010; 20

Veröffentlichungsdatum

01.04.2010

eISSN (Online)

1744-6880

Seiten

217-30

Kurzbeschreibung/Zielsetzung

An ADME (absorption, distribution, metabolism and excretion)-pharmacogenetics association study may identify functional variants relevant to the pharmacokinetics of lopinavir co-formulated with ritonavir (LPV/r), a first-line anti-HIV agent.